Pharma gives the middle finger to patients

KEY TAKEAWAY:Gilead, which recently acquired Kite Pharma in an all cash deal, said the list price for Yescarta, which is to be administered just once to each patient, would be $373,000. The cost is supposed to make us feel good because the price is well below that of the first drug in this new class such as $475,000 for Novartis’s  Kymriah.

Continue reading

It’s time to put patients first

We-care-about-YOUToo many people spend their whole career’s caring far too much about offending people, worrying if they cool enough for them, or asking themselves if they are judging me.  There comes a point in time when you can’t take it anymore because it’s stupid, and it’s not good for patients who are too damn important to ignore. At some companies it has made some DTC marketers  a punching bag–  a flighty, nervous wuss. But worse than that, it has made me some marketers who don’t take a stand for anything even though they it’s what’s best for patients. It has made too many people who stand in the middle for fear of alienating others. Moving forward you need to be able to say  “No more. Not today. ” Continue reading